Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Stopped early · Phase 1/Phase 2
Conditions studied: Carcinoma, Non-Small-Cell Lung
In brief
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination. Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated. Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.
Key facts
- Study ID
- NCT04585815
- Run by
- Pfizer
- People needed
- 34
- Starts
- 2020-11-10
- Expected to finish
- 2024-10-29
- Last updated by the study team
- 2026-01-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- UCSD Medical Center - Encinitas — Encinitas, California, United States
- California Cancer Associates for Research and Excellence, Inc (cCARE) — Fresno, California, United States
- The Oncology Institute of Hope and Innovation — Glendale, California, United States
- Koman Family Outpatient Pavilion — La Jolla, California, United States
- Sulpizio Cardiovascular Center at UC San Diego Health — La Jolla, California, United States
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) — La Jolla, California, United States
- UC San Diego Moores Cancer Center - Investigational Drug Services — La Jolla, California, United States
- UCSD Perlman Medical Offices — La Jolla, California, United States
- UC San Diego Moores Cancer Center — La Jolla, California, United States
- The Oncology Institute of Hope and Innovation — Long Beach, California, United States
- The Oncology Institute of Hope and Innovation — Los Angeles, California, United States
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
- UC San Diego Medical Center - Hillcrest — San Diego, California, United States
- The Oncology Institute of Hope and Innovation — Santa Ana, California, United States
- UCSD Medical Center - Vista — Vista, California, United States
- The Oncology Institute of Hope and Innovation — Whittier, California, United States
- AdventHealth Celebration Infusion Center — Celebration, Florida, United States
- AdventHealth Medical Group Oncology Research at Celebration — Celebration, Florida, United States
- Advent Health Orlando - Investigational Drug Services — Orlando, Florida, United States
- AdventHealth Orlando Infusion Center — Orlando, Florida, United States
- AdventHealth Orlando — Orlando, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Henry Ford Medical Center - Fairlane — Dearborn, Michigan, United States
- City of Hope Investigational Drug Services (IDS) — Duarte, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.